The Need for Standardization of In Vitro Release Testing (IVRT)
Kailas Thakker, PhD, Co-founder of Tergus
Standardization of In Vitro Release test (IVRT) is a step to achieving consistency in release rate data in a market place where different types of apparatus and techniques are used frequently and continuously. It is an important next step to ensure consistency and success.
Once some standardization has taken place, scientists and regulators will be able to use a properly developed In Vitro Release test to develop specifications and criteria for release of an API from formulation matrix.
When used in early phase of development to select a clinical candidate, it will allow scientists a better than fair chance of successful performance of that dosage form in clinic. In late phase of development, the specifications and criteria built into the release rate will assure consistency in manufacturing of that dosage form.
When applied to multiple products by the same or different manufactures, properly developed specifications for release rate and adherence thereof will allow better comparisons between dosage forms.
- Tergus Pharma Announces New Commercial Manufacturing Facility and Partnership with Great Point Partners
- Large vs. Small – Why small, agile manufacturing operations trump large companies
- SUPAC-SS GUIDANCE EXPLAINED – When In Vitro Release Testing (IVRT) is Required for Semisolid Products
- Continuous Manufacturing and Semi-Solids
- Skin Cancer Drug Fast-tracked to Patients in UK